If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in ...

Arexvy is currently approved for use in all individuals aged 60 and older, as well as for high-risk individuals aged 50-59.

The UK's medicines regulator has warned NHS healthcare staff about an increased risk of a condition affecting the nerves in ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

KIRKLAND, QC, Sept. 19, 2024 /CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in ...

Pfizer Inc. today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial MONeT, evaluating two doses of ABRYSVO vaccine in ...

The approval makes Pfizer’s Abrysvo the first RSV vaccine indicated for adults younger than 50, the company said. Photo: Carlo Allegri/REUTERS ...

The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus ...

Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown efficacy in immunocompromised adults, the pharma announced Monday. In substudy B of Pfizer’s ongoing Phase 3 MONeT trial, Abrysvo ...

Pfizer said on Monday its respiratory syncytial virus (RSV) vaccine Abrysvo generated a strong immune response in a late-stage study of four groups of adults aged 18 and older with a compromised ...